Is AbbVie (ABBV) One of the 10 Best July Dividend Stocks to Buy?

AbbVie Inc. (NYSE:ABBV) will trade ex-dividend on July 15, putting it among the 10 Best July Dividend Stocks to Buy.

Is AbbVie (ABBV) One of the 10 Best July Dividend Stocks to Buy?

On June 27, AbbVie Inc. (NYSE:ABBV) said the Food and Drug Administration approved Skyrizi for pediatric patients with psoriasis. The company said Skyrizi, or risankizumab-rzaa, can now be used in patients aged six years and older to treat moderate-to-severe plaque psoriasis or active psoriatic arthritis.

AbbVie also received approval for a new 55 mg pre-filled syringe for patients weighing less than 40 kg, or about 88 pounds. Patients weighing 40 kg or more can continue using the currently available 150 mg pre-filled syringe (PFS) and Pen.

According to AbbVie, about 30% of people who develop psoriasis experience symptoms before the age of 18. Skyrizi is also approved to treat adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis.

AbbVie Inc. (NYSE:ABBV) is a global, diversified, research-based biopharmaceutical company. It focuses on the research and development, manufacturing, commercialization, and sale of medicines and therapies.

While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 Dividend Stocks with 10%+ Yield and Billionaire Steven Cohen’s Top 11 Dividend Stock Picks

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1